🛑
Novo Nordisk A/S: Evoke Phase 3 studies showed no statistically significant reduction in Alzheimer's disease progression Bagsværd,
Denmark, November 24, 2025 - Novo Nordisk today announced key results from the two-year primary analysis of the Evoke and Evoke+ Phase 3 studies in symptomatic early-stage Alzheimer's disease.
The two randomized, double-blind studies included a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo in addition to standard of care.
The decision to develop semaglutide for the Alzheimer's disease indication was based on data from clinical practice, preclinical models and post-hoc analyses from diabetes and obesity studies.
The evoke and evoke+ studies could not confirm the superiority of semaglutide over placebo in slowing the progression of Alzheimer's disease as measured by the change from baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score.
Although treatment with semaglutide led to an improvement in Alzheimer's biomarkers in both studies, this did not result in a delay in disease progression.
